We are actively engaged in studies linking clinical outcomes to pathophysiology, also on a molecular basis. Often based on outcomes from and also involving omics studies, we study the functionality of genes and proteins in disease.
We use molecular approaches:
- in cells and tissues from patients,
- in cell lines
- and in animal models.
In vivo and in vitro silencing and overexpression of genes are now established techniques that are operational at the UMCG and GRIP, including the development of knock out and transgenic mouse models, and the use of RNA interference and pharmacological modulation of cells and tissue slices.
Fundamental to this line of research is the exploration of intracellular and intercellular pathways and interactions. This exploration is highly relevant for
- tissue repair,
- disease development, progression and remission,
- as well as for the exploration of novel drug targets.